Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: from bench to clinical use

被引：9
作者：
Sotomi, Yohei [1 ]
Suwannasom, Pannipa [1 ,2 ,3 ]
Tenekecioglu, Erhan [2 ]
Tateishi, Hiroki [2 ]
Abdelghani, Mohammad [1 ]
Serruys, Patrick W. [4 ]
Onuma, Yoshinobu [2 ]
机构：
[1] Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands
[2] Erasmus MC, ThoraxCtr, Rotterdam, Netherlands
[3] Chiang Mai Univ, Fac Med, Northern Region Heart Ctr, Chiang Mai, Thailand
[4] Imperial Coll London, NHLI, Int Ctr Circulatory Hlth, London, England
来源：
EXPERT REVIEW OF CARDIOVASCULAR THERAPY | 2015年 / 13卷 / 10期
关键词：
bioresorbable vascular scaffold; drug-eluting stent; intravascular imaging; percutaneous coronary intervention; randomized controlled trial;
D O I：
10.1586/14779072.2015.1089172
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Drug-eluting stents have significantly improved the outcomes of percutaneous coronary intervention by substantially reducing in-stent restenosis and stent thrombosis. However, a potential limitation of these stents is the permanent presence of a metallic foreign body within the artery, which may cause vascular inflammation, restenosis, thrombosis, neoatherosclerosis, permanent impairment of the physiological vasomotor function and interference with potential future grafting of the stented segment. Bioresorbable scaffolds have the potential to overcome these limitations as they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage and restoring pulsatility, cyclical strain, physiological shear stress and mechanotransduction. This article presents a comparison between the most widespread bioresorbable vascular scaffold 'Absorb BVS' and second-generation drug-eluting stent (cobalt chromium everolimus-eluting stent) from bench to clinical use.
引用
收藏
页码：1127 / 1145
页数：19
相关论文
共 97 条
  • [41] Attizzani G.F., Ohno Y., Capodanno D., Et al., New insights on acute expansion and longitudinal elongation of bioresorbable vascular scaffolds in vivo and at bench test: A note of caution on reliance to compliance charts and nominal length, Catheter Cardiovasc Interv, 85, 4, pp. E99-e107, (2015)
  • [42] Karabulut A., Demirci Y., Cutting balloon use may ease the optimal apposition of bioresorbable vascular scaffold in in-stent stenosis, Postepy Kardiol Interwencyjnej, 11, 1, pp. 64-66, (2015)
  • [43] Miyazaki T., Panoulas V.F., Sato K., Et al., In-Scaffold Restenosis in a Previous Left Main Bifurcation Lesion Treated With Bioresorbable Scaffold V-Stenting, JACC Cardiovasc Intervent, 8, 1 PA, pp. e7-e10, (2015)
  • [44] Naganuma T., Basavarajaiah S., Latib A., Et al., Use of BVS in a chronic total occlusion with bifurcation lesion, Int J Cardiol, 167, 5, pp. e129-e131, (2013)
  • [45] Roleder T., Parma Z., Smolka G., Et al., Optical Coherence Tomography Imaging of Everolimus-eluting Bioresorbable Vascular Scaffold Implanted into Coronary Vein Graft at 3-month Follow-up, (2014)
  • [46] Ong P.J.L., Jafary F.H., Ho H.H., First-in-man" use of bioresorbable vascular scaffold in saphenous vein graft, EuroIntervention, 9, 1, (2013)
  • [47] Tamburino C., Latib A., Van Geuns R.-J.M., Et al., Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: A European perspective, EuroIntervention, 11, 1, pp. 45-52, (2015)
  • [48] Gomez-Lara J., Diletti R., Brugaletta S., Et al., Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: An ABSORB cohort B trial sub-study, EuroIntervention, 8, 2, pp. 214-224, (2012)
  • [49] Onuma Y., Serruys P.W., Muramatsu T., Et al., Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: Optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions), JACC. Cardiovascular Interventions, 7,
  • [50] Farooq V., Gomez-Lara J., Brugaletta S., Et al., Proximal and distal maximal luminal diameters as a guide to appropriate deployment of the ABSORB everolimus-eluting bioresorbable vascular scaffold: A sub-study of the ABSORB Cohort B and the on-going ABSORB EXTEND Single Arm Study, Catheter Cardiovasc Interv, 79, 6, pp. 880-888, (2012)
12345678910